Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Nov 24:13:1058748.
doi: 10.3389/fimmu.2022.1058748. eCollection 2022.

Profiling the B cell immune response elicited by vaccination against the respiratory virus SARS-CoV-2

Affiliations
Review

Profiling the B cell immune response elicited by vaccination against the respiratory virus SARS-CoV-2

Elena Pettini et al. Front Immunol. .

Abstract

B cells play a fundamental role in host defenses against viral infections. Profiling the B cell response elicited by SARS-CoV-2 vaccination, including the generation and persistence of antigen-specific memory B cells, is essential for improving the knowledge of vaccine immune responsiveness, beyond the antibody response. mRNA-based vaccines have shown to induce a robust class-switched memory B cell response that persists overtime and is boosted by further vaccine administration, suggesting that memory B cells are critical in driving a recall response upon re-exposure to SARS-CoV-2 antigens. Here, we focus on the role of the B cell response in the context of SARS-CoV-2 vaccination, offering an overview of the different technologies that can be used to identify spike-specific B cells, characterize their phenotype using machine learning approaches, measure their capacity to reactivate following antigen encounter, and tracking the maturation of the B cell receptor antigenic affinity.

Keywords: B cell ELISpot; BCR repertoire; COVID-19 vaccines; SARS-CoV-2; computational flow cytometry; memory B cells; respiratory virus.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Workflow for the identification of vaccine-induced spike-specific B cells. Schematic representation of different technologies to detect antigen-specific B cells in blood samples collected from SARS-CoV-2 vaccinated subjects. PBMC can be used for multiparametric flow cytometry analysis labelling cells with the fluorescent antigen as probe to identify rare antigen-specific B cells. Computational flow cytometry can be then applied to explore and visualize multiparametric flow cytometry data (fcs files) using specific tools and algorithms. Effector function of spike-specific memory B cells can be measured in PBMC by B-cell ELISpot technique upon in vitro restimulation of cells. High-throughput bulk RNA sequencing of BCR heavy-chain genes can be performed on whole blood to unravel the dynamics of the BCR repertoire.
Figure 2
Figure 2
Schematic gating strategy for the identification of spike-specific B cells. (A) Examples of different strategies that can be used for selecting the parent subset of B cells to be analyzed for the presence of spike-specific B cells. Starting from CD19+ B cells gated among live, singlet cells a, it can be selected the not-naïve B cells by excluding the IgD+CD27- cells b; the CD19+CD20+ c, switched MBC (IgD-IgM-, d, and the CD19-/low CD20- cells c CD38highCD27+ plasmablasts e. (B) Identification of antigen-specific-B cells using two fluorescent labelled spike proteins f, the full spike versus the RBD domain only g or versus the spike protein of a viral variant (var1, h).

Similar articles

Cited by

References

    1. McHeyzer-Williams LJ, McHeyzer-Williams MG. Antigen-specific memory b cell development. Annu Rev Immunol (2005) 23:487–513. doi: 10.1146/annurev.immunol.23.021704.115732 - DOI - PubMed
    1. Guerrini G, Magrì D, Gioria S, Medaglini D, Calzolai L. Characterization of nanoparticles-based vaccines for COVID-19. Nat Nanotechnol (2022) 17:570–6. doi: 10.1038/s41565-022-01129-w - DOI - PubMed
    1. Notarte KI, Ver AT, Velasco JV, Pastrana A, Catahay JA, Salvagno GL, et al. Effects of age, sex, serostatus, and underlying comorbidities on humoral response post-SARS-CoV-2 pfizer-BioNTech mRNA vaccination: A systematic review. Crit Rev Clin Lab Sci (2022) 59:373–90. doi: 10.1080/10408363.2022.2038539 - DOI - PMC - PubMed
    1. Ciabattini A, Garagnani P, Santoro F, Rappuoli R, Franceschi C, Medaglini D. Shelter from the cytokine storm: Pitfalls and prospects in the development of SARS-CoV-2 vaccines for an elderly population. Semin Immunopathol (2020) 42:619–34. doi: 10.1007/s00281-020-00821-0 - DOI - PMC - PubMed
    1. Fiorino F, Sicuranza A, Ciabattini A, Santoni A, Pastore G, Simoncelli M, et al. The slower antibody response in myelofibrosis patients after two doses of mRNA SARS-CoV-2 vaccine calls for a third dose. Biomedicines (2021) 9:1480. doi: 10.3390/biomedicines9101480 - DOI - PMC - PubMed

Substances